California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
Screening List of ICD-9-CM Codes for Casefinding
Certain ICD-9-CM* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.
Other ICD-9-CM Code Editions:
The following information was taken directly from the SEER web site.
ICD-9-CM* CODE |
Description |
042 |
AIDS (review cases for AIDS-related malignancies) |
140.0 – 208.9 |
Malignant neoplasms (primary and secondary) |
203.1 |
Plasma cell leukemia (9733/3) |
205.1 |
Chronic neutrophilic leukemia (9963/3) |
225.0 – 227.4 |
Benign central nervous system neoplasms |
230.0 – 234.9 |
Carcinoma in situ (exclude skin codes 232.0-232.9, and cervix code 233.1) |
235.0 – 238.9 |
Neoplasms of uncertain behavior |
236.2 |
Ovarian neoplasms of uncertain behavior (8442/1, 8451/1, 8462/1, 8472/1, 8473/1) |
237.0 – 237.9 |
Central nervous system neoplasms of uncertain behavior |
238.4 |
Polycythemia vera (9950/3) |
238.6 |
Solitary plasmacytoma (9731/3) |
238.6 |
Extramedullary plasmacytoma (9734/3) |
238.71 |
Essential thrombocythemia (was 238.7; 9962/3) Essential (hemorrhagic) thrombocythemia Essential thrombocytosis Idiopathic (hemorrhagic) thrombocythemia Primary thrombocytosis |
238.72 |
Low grade myelodysplastic syndrome lesions Refractory anemia (was 284.9; 9980/3) Refractory anemia with ringed sideroblasts (RARS) (was 285.0; 9982/3) Refractory cytopenia with multilineage dysplasia (RCMD) (was 238.7; 9985/3) Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) was 238.7; 9985/3) |
238.73 |
High grade myelodysplastic syndrome lesions Refractory anemia with excess blasts-1 (RAEB-1) (was 285.0; 9983/3) Refractory anemia with excess blasts-2 (RAEB-2) (was 285.0; 9983/3) |
238.74 |
Myelodysplastic syndrome with 5q deletion (was 238.7; 9986/3) 5q minus syndrome NOS Excludes: constitutional 5q deletion (758.39) (not reportable) high grade myelodysplastic syndrome with 5q deletion (238.73) |
238.75 |
Myelodysplastic syndrome, unspecified (was 238.7; 9985/3, 9989/3) |
238.76 |
Myelosclerosis with myeloid metaplasia (9961/3) Agnogenic myeloid metaplasia Idiopathic myelofibrosis (chronic) Myelosclerosis with myeloid metaplasia Primary myelofibrosis Excludes: myelofibrosis NOS (289.83) myelophthisic anemia (284.2) (not reportable) myelophthisis (284.2) (not reportable) secondary myelofibrosis (289.83) |
238.79 |
Other lymphatic and hematopoietic tissues Lymphoproliferative disease (chronic) NOS (was 238.7; 9970/1) Megakaryocytic myelosclerosis (was 238.7; 9961/3) Myeloproliferative disease (chronic) NOS (was 238.7; 9960/3) Panmyelosis (acute) (was 238.7; 9931/3) |
239.0 – 239.9 |
Neoplasms of unspecified nature |
273.2 |
Gamma heavy chain disease Franklin's disease |
273.3 |
Waldenstrom's macroglobulinemia |
273.9 |
Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes) |
288.3 |
Hypereosinophilic syndrome (9964/3) |
289.83 |
Myelofibrosis (9932/3) Myelofibrosis, NOS Secondary myelofibrosis Code first underlying disorder, such as: malignant neoplasm of breast (174.0-174.9, 175.0-175.9) Excludes: Idiopathic myelofibrosis (238.76) leukoerythroblastic anemia (238.2) (not reportable) myelofibrosis with myeloid metaplasia (238.76) myelophthisic anemia (284.2) (not reportable) myelophthisis (284.2) (not reportable) primary myelofibrosis (238.76) |
289.89 |
Other specified diseases of blood and blood-forming organs |
V07.3 |
Other prophylactic chemotherapy |
V07.8 |
Other specified prophylactic measures |
V10.0 – V10.9 |
Personal history of malignant neoplasms |
V58.0 |
Radiotherapy session |
V58.1 |
Maintenance chemotherapy |
V66.1 |
Convalescence following radiotherapy |
V66.2 |
Convalescence following chemotherapy |
V67.1 |
Follow-up exam following radiotherapy |
V67.2 |
Follow-up exam following chemotherapy |
V71.1 |
Observation for suspected malignant neoplasm |
V76.0 – V76.9 |
Special screening for malignant neoplasms |
V86 |
Estrogen receptor status |
* International Classification of Diseases, 9th Revision, Clinical Modification, 4th ed.
Code 042 is not a combination code of AIDS with specified malignancies.
Prostatic Intraepithelial Neoplasia (PIN III), morphology code 8148/2 is not reportable to the CCR.
Pilocytic/juvenile astrocytoma, morphology code 9421, is reportable as a /3 behavior code and is assigned a regular tumor sequence number per SEER requirements, effective with cases diagnosed 1/1/2001 and forward.
Ovarian borderline cystadenomas, morphology codes 8442/1, 8451/1, 8462/1, 8472/1 and 8473/1, which changed behavior codes from /3 to /1 will continue to be reportable to the CCR. These tumors are to be sequenced following the American College of Surgeons guideline for benign tumors.